Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
86.6M
-
Number of holders
-
214
-
Total 13F shares, excl. options
-
102M
-
Shares change
-
+618K
-
Total reported value, excl. options
-
$953M
-
Value change
-
-$3.41M
-
Put/Call ratio
-
1.01
-
Number of buys
-
114
-
Number of sells
-
-99
-
Price
-
$9.37
Significant Holders of Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share (SNDX) as of Q2 2025
267 filings reported holding SNDX - Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share as of Q2 2025.
Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share (SNDX) has 214 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 102M shares
.
Largest 10 shareholders include BlackRock, Inc. (10.5M shares), Kynam Capital Management, LP (8.52M shares), GOLDMAN SACHS GROUP INC (5.8M shares), VANGUARD GROUP INC (5.03M shares), Eversept Partners, LP (4.07M shares), BANK OF AMERICA CORP /DE/ (3.84M shares), STATE STREET CORP (3.44M shares), STEMPOINT CAPITAL LP (2.37M shares), FRANKLIN RESOURCES INC (2.36M shares), and Point72 Asset Management, L.P. (2.13M shares).
This table shows the top 214 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.